Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ
Tytuł pozycji:

Modeling of tumor response to macrophage and T lymphocyte interactions in the liver metastatic microenvironment.

Tytuł :
Modeling of tumor response to macrophage and T lymphocyte interactions in the liver metastatic microenvironment.
Autorzy :
Curtis LT; Department of Bioengineering, University of Louisville, Lutz Hall 419, Louisville, KY, 40292, USA.
Sebens S; Institute for Experimental Cancer Research, Christian-Albrechts-University Kiel (CAU), Kiel, Germany.; University Medical Center Schleswig-Holstein (UK-SH), Campus Kiel, Kiel, Germany.
Frieboes HB; Department of Bioengineering, University of Louisville, Lutz Hall 419, Louisville, KY, 40292, USA. .; Center for Predictive Medicine, University of Louisville, Louisville, KY, USA. .; James Graham Brown Cancer Center, University of Louisville, Louisville, KY, USA. .
Pokaż więcej
Źródło :
Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2021 May; Vol. 70 (5), pp. 1475-1488. Date of Electronic Publication: 2020 Nov 12.
Typ publikacji :
Journal Article
Język :
Imprint Name(s) :
Publication: Berlin : Springer Verlag
Original Publication: Berlin ; New York, NY : Springer International, c1982-
MeSH Terms :
Models, Immunological*
Liver Neoplasms/*immunology
Th1 Cells/*immunology
Th2 Cells/*immunology
Cell Communication ; Cell Differentiation ; Cytokines/metabolism ; Cytotoxicity, Immunologic ; Humans ; Liver Neoplasms/therapy ; Lymphocyte Activation ; Neoplasm Metastasis ; Th1-Th2 Balance ; Tumor Microenvironment
References :
Bremnes RM, Donnem T, Al-Saad S, Al-Shibli K, Andersen S, Sirera R, Camps C, Marinez I, Busund LT (2011) The role of tumor stroma in cancer progression and prognosis: emphasis on carcinoma-associated fibroblasts and non-small cell lung cancer. J Thorac Oncol 6(1):209–217. (PMID: 10.1097/JTO.0b013e3181f8a1bd21107292)
Wu J, Lanier LL (2003) Natural killer cells and cancer. Adv Cancer Res 90:127–156. (PMID: 10.1016/s0065-230x(03)90004-214710949)
Wu L, Saxena S, Awaji M, Singh RK (2019) Tumor-associated neutrophils in cancer: going pro. Cancers (Basel). (PMID: 10.3390/cancers11040564318618727263419)
Ma Y, Shurin GV, Peiyuan Z, Shurin MR (2013) Dendritic cells in the cancer microenvironment. J Cancer 4(1):36–44. (PMID: 10.7150/jca.504623386903)
Olingy CE, Dinh HQ, Hedrick CC (2019) Monocyte heterogeneity and functions in cancer. J Leukoc Biol 106(2):309–322. (PMID: 10.1002/JLB.4RI0818-311R307761486658332)
Disis ML (2010) Immune regulation of cancer. J Clin Oncol 28(29):4531–4538. (PMID: 10.1200/JCO.2009.27.2146205164283041789)
Yao R-R, Li J-H, Zhang R, Chen R-X, Wang Y-H (2018) M2-polarized tumor-associated macrophages facilitated migration and epithelial–mesenchymal transition of HCC cells via the TLR4/STAT3 signaling pathway. World J Surg Oncol 16:9. (PMID: 10.1186/s12957-018-1312-y293387425771014)
Yuan A, Hsiao Y-J, Chen H-Y, Chen H-W, Ho C-C, Chen Y-Y, Liu Y-C, Hong T-H, Yu S-L, Chen JJW, Yang P-C (2015) Opposite effects of M1 and M2 macrophage subtypes on lung cancer progression. Sci Rep 5:14273. (PMID: 10.1038/srep14273)
Italiani P, Boraschi D (2014) From monocytes to M1/M2 macrophages: phenotypical vs. functional differentiation. Front Immunol 5:514. (PMID: 10.3389/fimmu.2014.00514253686184201108)
Laoui D, Movahedi K, Van Overmeire E, Van den Bossche J, Schouppe E, Mommer C, Nikolaou A, Morias Y, De Baetselier P, Van Ginderachter JA (2011) Tumor-associated macrophages in breast cancer: distinct subsets, distinct functions. Int J Dev Biol 55(7–9):861–867. (PMID: 10.1387/ijdb.113371dl22161841)
Chanmee T, Ontong P, Konno K, Itano N (2014) Tumor-associated macrophages as major players in the tumor microenvironment. Cancers 6(3):1670–1690. (PMID: 10.3390/cancers6031670251254854190561)
Roca H, Varsos ZS, Sud S, Craig MJ, Ying C, Pienta KJ (2009) CCL2 and interleukin-6 promote survival of human CD11b(+) peripheral blood mononuclear cells and induce M2-type macrophage polarization. J Biol Chem 284(49):34342–34354. (PMID: 10.1074/jbc.M109.042671198337262797202)
Nielsen SR, Schmid MC (2017) Macrophages as key drivers of cancer progression and metastasis. Mediat Inflamm 2017:11. (PMID: 10.1155/2017/9624760)
Krenkel O, Tacke F (2017) Liver macrophages in tissue homeostasis and disease. Nat Rev Immunol 17(5):306–321. (PMID: 10.1038/nri.2017.1128317925)
Yuen GJ, Demissie E, Pillai S (2016) B lymphocytes and cancer: a love–hate relationship. Trends Cancer 2(12):747–757. (PMID: 10.1016/j.trecan.2016.10.010286268015472356)
Maher J, Davies ET (2004) Targeting cytotoxic T lymphocytes for cancer immunotherapy. Br J Cancer 91(5):817–821. (PMID: 10.1038/sj.bjc.6602022152663092409863)
Kondelkova K, Vokurkova D, Krejsek J, Borska L, Fiala Z, Ctirad A (2010) Regulatory T cells (TREG) and their roles in immune system with respect to immunopathological disorders. Acta med (Hradec Kral) 53(2):73–77. (PMID: 10.14712/18059694.2016.63)
Jiang Y, Li Y, Zhu B (2015) T-cell exhaustion in the tumor microenvironment. Cell Death Dis 6:e1792. (PMID: 10.1038/cddis.2015.162260869654669840)
Zarour HM (2016) Reversing T-cell dysfunction and exhaustion in cancer. Clin Cancer Res 22(8):1856–1864. (PMID: 10.1158/1078-0432.CCR-15-1849270847394872712)
Peranzoni E, Lemoine J, Vimeux L, Feuillet V, Barrin S, Kantari-Mimoun C, Bercovici N, Guerin M, Biton J, Ouakrim H, Regnier F, Lupo A, Alifano M, Damotte D, Donnadieu E (2018) Macrophages impede CD8 T cells from reaching tumor cells and limit the efficacy of anti-PD-1 treatment. Proc Natl Acad Sci U S A 115(17):E4041–E4050. (PMID: 10.1073/pnas.1720948115296321965924916)
Xu X, Wang R, Su Q, Huang H, Zhou P, Luan J, Liu J, Wang J, Chen X (2016) Expression of Th1-, Th2- and Th17-associated cytokines in laryngeal carcinoma. Oncol Lett 12(3):1941–1948. (PMID: 10.3892/ol.2016.4854275881434998098)
De Monte L, Reni M, Tassi E, Clavenna D, Papa I, Recalde H, Braga M, Di Carlo V, Doglioni C, Protti MP (2011) Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer. J Exp Med 208(3):469–478. (PMID: 10.1084/jem.20101876213393273058573)
Muraille E, Leo O, Moser M (2014) TH1/TH2 paradigm extended: macrophage polarization as an unappreciated pathogen-driven escape mechanism? Front Immunol 5:603. (PMID: 10.3389/fimmu.2014.00603255054684244692)
Bar-Or RL (2000) Feedback mechanisms between T helper cells and macrophages in the determination of the immune response. Math Biosci 163(1):35–58. (PMID: 10.1016/s0025-5564(99)00046-210652844)
den Breems NY, Eftimie R (2016) The re-polarisation of M2 and M1 macrophages and its role on cancer outcomes. J Theor Biol 390:23–39. (PMID: 10.1016/j.jtbi.2015.10.034)
Mahlbacher G, Curtis LT, Lowengrub J, Frieboes HB (2018) Mathematical modeling of tumor-associated macrophage interactions with the cancer microenvironment. J Immunother Cancer 6(1):10. (PMID: 10.1186/s40425-017-0313-7293823955791333)
Norton KA, Jin K, Popel AS (2018) Modeling triple-negative breast cancer heterogeneity: effects of stromal macrophages, fibroblasts and tumor vasculature. J Theor Biol 452:56–68. (PMID: 10.1016/j.jtbi.2018.05.003297509996127870)
Bracci L, Schiavoni G, Sistigu A, Belardelli F (2014) Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer. Cell Death Differ 21(1):15–25. (PMID: 10.1038/cdd.2013.6723787994)
Chen D, Bobko AA, Gross AC, Evans R, Marsh CB, Khramtsov VV, Eubank TD, Friedman A (2014) Involvement of tumor macrophage HIFs in chemotherapy effectiveness: mathematical modeling of oxygen, pH, and glutathione. PLoS ONE. (PMID: 10.1371/journal.pone.0107511259196884281253)
Kareva I, Waxman DJ, Klement GL (2015) Metronomic chemotherapy: an attractive alternative to maximum tolerated dose therapy that can activate anti-tumor immunity and minimize therapeutic resistance. Cancer Lett 358(2):100–106. (PMID: 10.1016/j.canlet.2014.12.039)
Sun Y, Campisi J, Higano C, Beer TM, Porter P, Coleman I, True L, Nelson PS (2012) Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B. Nat Med 18(9):1359–1368. (PMID: 10.1038/nm.2890228637863677971)
Leonard F, Curtis LT, Hamed AR, Zhang C, Chau E, Sieving D, Godin B, Frieboes HB (2020) Nonlinear response to cancer nanotherapy due to macrophage interactions revealed by mathematical modeling and evaluated in a murine model via CRISPR-modulated macrophage polarization. Cancer Immunol Immunother 69(5):731–744. (PMID: 10.1007/s00262-020-02504-z32036448)
Leonard F, Curtis LT, Ware MJ, Nosrat T, Liu X, Yokoi K, Frieboes HB, Godin B (2017) Macrophage polarization contributes to the anti-tumoral efficacy of mesoporous nanovectors loaded with albumin-bound paclitaxel. Front Immunol 8:693. (PMID: 10.3389/fimmu.2017.00693286703135472662)
Leonard F, Curtis LT, Yesantharao P, Tanei T, Alexander JF, Wu M, Lowengrub J, Liu X, Ferrari M, Yokoi K, Frieboes HB, Godin B (2016) Enhanced performance of macrophage-encapsulated nanoparticle albumin-bound-paclitaxel in hypo-perfused cancer lesions. Nanoscale 8(25):12544–12552. (PMID: 10.1039/C5NR07796F268182124919151)
Owen MR, Stamper IJ, Muthana M, Richardson GW, Dobson J, Lewis CE, Byrne HM (2011) Mathematical modeling predicts synergistic antitumor effects of combining a macrophage-based, hypoxia-targeted gene therapy with chemotherapy. Cancer Res 71(8):2826–2837. (PMID: 10.1158/0008-5472.can-10-2834213639143527892)
Mahlbacher GE, Reihmer KC, Frieboes HB (2019) Mathematical modeling of tumor-immune cell interactions. J Theor Biol 469:47–60. (PMID: 10.1016/j.jtbi.2019.03.002308360736579737)
Macklin P, McDougall S, Anderson ARA, Chaplain MAJ, Cristini V, Lowengrub J (2009) Multiscale modelling and nonlinear simulation of vascular tumour growth. J Math Biol 58(4–5):765–798. (PMID: 10.1007/s00285-008-0216-918781303)
Wu M, Frieboes HB, McDougall SR, Chaplain MAJ, Cristini V, Lowengrub J (2013) The effect of interstitial pressure on tumor growth: coupling with the blood and lymphatic vascular systems. J Theor Biol 320:131–151. (PMID: 10.1016/j.jtbi.2012.11.03123220211)
van de Ven AL, Wu M, Lowengrub J, McDougall SR, Chaplain MA, Cristini V, Ferrari M, Frieboes HB (2012) Integrated intravital microscopy and mathematical modeling to optimize nanotherapeutics delivery to tumors. AIP Adv 2(1):11208. (PMID: 10.1063/1.369906022489278)
Lewis C, Murdoch C (2005) Macrophage responses to hypoxia: implications for tumor progression and anti-cancer therapies. Am J Pathol 167(3):627–635. (PMID: 10.1016/S0002-9440(10)62038-X)
McDougall SR, Anderson ARA, Chaplain MAJ (2006) Mathematical modelling of dynamic adaptive tumour-induced angiogenesis: clinical implications and therapeutic targeting strategies. J Theor Biol 241(3):564–589. (PMID: 10.1016/j.jtbi.2005.12.02216487543)
Frieboes HB, Curtis LT, Wu M, Kani K, Mallick P (2015) Simulation of the protein-shedding kinetics of a fully vascularized tumor. Cancer Inform 14:163–175. (PMID: 10.4137/CIN.S35374267158304687979)
Spinney L (2006) Caught in time. Nature 442(7104):736–738. (PMID: 10.1038/442736a16915260)
Martinez FO, Gordon S (2014) The M1 and M2 paradigm of macrophage activation: time for reassessment. F1000Prime Rep 6:13. (PMID: 10.12703/P6-13246692943944738)
Reichel D, Curtis LT, Ehlman E, Mark Evers B, Rychahou P, Frieboes HB, Bae Y (2017) Development of halofluorochromic polymer nanoassemblies for the potential detection of liver metastatic colorectal cancer tumors using experimental and computational approaches. Pharm Res 34(11):2385–2402. (PMID: 10.1007/s11095-017-2245-9288404325645260)
Curtis LT, Rychahou P, Bae Y, Frieboes HB (2016) A Computational/experimental assessment of antitumor activity of polymer nanoassemblies for pH-controlled drug delivery to primary and metastatic tumors. Pharm Res 33(10):2552–2564. (PMID: 10.1007/s11095-016-1981-627356524)
Curtis LT, Frieboes HB (2019) Modeling of combination chemotherapy and immunotherapy for lung cancer. Conf Proc IEEE Eng Med Biol Soc 2019:273–276. (PMID: 10.1109/EMBC.2019.88575666986319)
Lee C, Jeong H, Bae Y, Shin K, Kang S, Kim H, Oh J, Bae H (2019) Targeting of M2-like tumor-associated macrophages with a melittin-based pro-apoptotic peptide. J Immunother Cancer 7(1):147. (PMID: 10.1186/s40425-019-0610-4311746106555931)
Cui YL, Li HK, Zhou HY, Zhang T, Li Q (2013) Correlations of tumor-associated macrophage subtypes with liver metastases of colorectal cancer. Asian–Pac J Cancer Prev 14(2):1003–1007. (PMID: 10.7314/apjcp.2013.14.2.100323621176)
Zhang M, He Y, Sun X, Li Q, Wang W, Zhao A, Di W (2014) A high M1/M2 ratio of tumor-associated macrophages is associated with extended survival in ovarian cancer patients. J Ovarian Res 7:19. (PMID: 10.1186/1757-2215-7-19245077593939626)
Monu NR, Frey AB (2012) Myeloid-derived suppressor cells and anti-tumor T cells: a complex relationship. Immunol Investig 41(6–7):595–613. (PMID: 10.3109/08820139.2012.673191)
Bodogai M, Moritoh K, Lee-Chang C, Hollander CM, Sherman-Baust CA, Wersto RP, Araki Y, Miyoshi I, Yang L, Trinchieri G, Biragyn A (2015) Immunosuppressive and prometastatic functions of myeloid-derived suppressive cells rely upon education from tumor-associated B cells. Cancer Res 75(17):3456–3465. (PMID: 10.1158/0008-5472.CAN-14-3077261839244558269)
Namm JP, Li Q, Lao X, Lubman DM, He J, Liu Y, Zhu J, Wei S, Chang AE (2012) B lymphocytes as effector cells in the immunotherapy of cancer. J Surg Oncol 105(4):431–435. (PMID: 10.1002/jso.2209321898417)
Sarvaria A, Madrigal JA, Saudemont A (2017) B cell regulation in cancer and anti-tumor immunity. Cell Mol Immunol 14(8):662–674. (PMID: 10.1038/cmi.2017.35286262345549607)
Erdogan B, Webb DJ (2017) Cancer-associated fibroblasts modulate growth factor signaling and extracellular matrix remodeling to regulate tumor metastasis. Biochem Soc Trans 45(1):229–236. (PMID: 10.1042/BST20160387282026775371349)
Hudson SV, Dolin CE, Poole LG, Massey VL, Wilkey D, Beier JI, Merchant ML, Frieboes HB, Arteel GE (2017) Modeling the kinetics of integrin receptor binding to hepatic extracellular matrix proteins. Sci Rep 7(1):12444. (PMID: 10.1038/s41598-017-12691-y289635355622105)
Hudson SV, Miller HA, Mahlbacher GE, Saforo D, Beverly LJ, Arteel GE, Frieboes HB (2019) Computational/experimental evaluation of liver metastasis post hepatic injury: interactions with macrophages and transitional ECM. Sci Rep 9(1):15077. (PMID: 10.1038/s41598-019-51249-y316362966803648)
Akinleye A, Rasool Z (2019) Immune checkpoint inhibitors of PD-L1 as cancer therapeutics. J Hematol Oncol 12(1):92. (PMID: 10.1186/s13045-019-0779-5314881766729004)
Feins S, Kong W, Williams EF, Milone MC, Fraietta JA (2019) An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer. Am J Hematol 94(S1):S3–S9. (PMID: 10.1002/ajh.2541830680780)
Rahn S, Kruger S, Mennrich R, Goebel L, Wesch D, Oberg HH, Vogel I, Ebsen M, Rocken C, Helm O, Sebens S (2019) POLE Score: a comprehensive profiling of programmed death 1 ligand 1 expression in pancreatic ductal adenocarcinoma. Oncotarget 10(16):1572–1588. (PMID: 10.18632/oncotarget.26705308994266422186)
Thompson ED, Zahurak M, Murphy A, Cornish T, Cuka N, Abdelfatah E, Yang S, Duncan M, Ahuja N, Taube JM, Anders RA, Kelly RJ (2017) Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma. Gut 66(5):794–801. (PMID: 10.1136/gutjnl-2015-31083926801886)
Weiss JM, Guerin MV, Regnier F, Renault G, Galy-Fauroux I, Vimeux L, Feuillet V, Peranzoni E, Thoreau M, Trautmann A, Bercovici N (2017) The STING agonist DMXAA triggers a cooperation between T lymphocytes and myeloid cells that leads to tumor regression. Oncoimmunology 6(10):e1346765. (PMID: 10.1080/2162402X.2017.1346765291239605665074)
Thoreau M, Penny HL, Tan K, Regnier F, Weiss JM, Lee B, Johannes L, Dransart E, Le Bon A, Abastado JP, Tartour E, Trautmann A, Bercovici N (2015) Vaccine-induced tumor regression requires a dynamic cooperation between T cells and myeloid cells at the tumor site. Oncotarget 6(29):27832–27846. (PMID: 10.18632/oncotarget.4940263378374695029)
Grant Information :
R15CA203605 United States CA NCI NIH HHS
Contributed Indexing :
Keywords: Cancer immunotherapy; Cancer simulation; Liver metastasis; Mathematical modeling; T lymphocytes; Tumor-associated macrophages
Substance Nomenclature :
0 (Cytokines)
Entry Date(s) :
Date Created: 20201112 Date Completed: 20210504 Latest Revision: 20210504
Update Code :
Czasopismo naukowe
The dynamic interactions between macrophages and T-lymphocytes in the tumor microenvironment exert both antagonistic and synergistic functions affecting tumor growth. Extensive experimental effort has been expended to investigate immunotherapeutic strategies targeting macrophage polarization as well as T-cell activation with the goal to promote tumor cell killing and cancer elimination. However, these interactions remain poorly understood, and cancer immunotherapeutic strategies are often disappointing. The complex system encompassing innate and adaptive immune cell activity in response to tumor growth could benefit from a systems perspective built upon mathematical modeling. This study develops a modeling system to help evaluate the effects of macrophage and T-lymphocyte interactions on tumor growth. The system enables simulating the combined cytotoxic and tumor-promoting interactions of these two immune cell populations in a vascularized organ microenvironment, such as in liver metastases. A hypothetical immunotherapeutic strategy is simulated to increase the number of tumor-suppressive (M1-phenotype) vs. tumor-promoting (M2-phenotype) macrophages to gauge their effects on CD8 + T-cells and CD4 + T-helper cells, which in turn affect the macrophage functions. The results highlight the dynamic interactions between macrophages and T-lymphocytes in the tumor microenvironment and show that with the chosen set of parameter values, the overall cytotoxic effect from macrophages and T-lymphocytes obtained by driving the M1:M2 ratio higher could saturate and fail to achieve tumor regression. Further expansion of this modeling platform to include additional tumor-immune cell interactions, coupled with parameters representing particular tumor characteristics, could enable systematic evaluation of immunotherapeutic strategies tailored to patient-tumor specific conditions, including metastatic disease.
Erratum in: Cancer Immunol Immunother. 2021 Jan 5;:. (PMID: 33398392)

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies